MarketCap
Facebook
X
Telegram
Anika Therapeutics Balance Sheet 2025-2008 | ANIK
Brief overview of Anika Therapeutics's assets and capital
Balance sheet changes are traced across five available annual reports between 2015 and 2019.
The asset base progressed from $235.7 million to $330.7 million, equal to +40.3% overall and about 8.8% per year.
Liability growth of +70% exceeded asset growth of +40.3%, increasing reliance on outside funding.
Equity accounts for 87.2% of assets. Against the initial 89.4%, the capital position looks resilient.
Cash exceeds interest-bearing debt, producing net debt of -$135 million. The balance sheet therefore carries a net cash position.
The cash reserve occupies 47.6% of the balance sheet, previously 47%. It is one marker of short-term resilience.
Retained earnings reached $245.4 million, changing +80.9% over the period. A positive accumulated result supports equity.
Overall picture
Anika Therapeutics's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Anika Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-31.2 M | -29.7 M | -41 M | -57.5 M | -75.1 M | - | -135 M | -89 M | -133 M | -104 M | -111 M | -100 M | -63.3 M | -34.5 M | -24.6 M | -15.4 M | - | - |
Long Term Debt |
24.2 M | 24 M | 25.9 M | 28.8 M | 19.2 M | - | - | - | - | - | - | - | - | 8 M | 9.6 M | 11.2 M | - | - |
Long Term Debt Current |
2.05 M | 1.92 M | 1.83 M | - | - | - | - | - | - | - | - | - | - | 1.6 M | 1.6 M | 1.6 M | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 26.1 M | 4.09 M | 6.05 M | 8.67 M | 7.62 M | 9.93 M | 11.1 M | 18.7 M | 23.5 M | - | - | - |
Total Current Liabilities |
21.9 M | 23.3 M | 31.1 M | 27.9 M | 29.8 M | 36.9 M | 16.3 M | 11.3 M | 13.1 M | 8.8 M | 17.3 M | 5.97 M | 9.28 M | 14.5 M | 14.5 M | 19.4 M | - | - |
Total Liabilities |
- | - | - | - | - | - | 42.3 M | 15.4 M | 19.1 M | 17.5 M | 24.9 M | 15.9 M | 20.4 M | 33.1 M | 38.1 M | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | 24.5 K | 180 K | 2.88 M | 2.87 M | 2.7 M | - | - |
Retained Earnings |
60.8 M | 71.7 M | 128 M | 211 M | 226 M | 221 M | 245 M | 218 M | 200 M | 168 M | 136 M | 105 M | 66.6 M | 46 M | 34.3 M | 25.8 M | - | - |
Total Assets |
190 M | 203 M | 271 M | 349 M | 348 M | 366 M | 331 M | 279 M | 283 M | 240 M | 236 M | 194 M | 156 M | 142 M | 133 M | 129 M | - | - |
Cash and Cash Equivalents |
57.5 M | 55.6 M | 68.7 M | 86.3 M | 94.4 M | 95.8 M | 157 M | 89 M | 133 M | 104 M | 111 M | 100 M | 63.3 M | 44.1 M | 35.8 M | 28.2 M | 24.4 M | 43.2 M |
Book Value |
190 M | 203 M | 271 M | 349 M | 348 M | 366 M | 288 M | 264 M | 263 M | 223 M | 211 M | 178 M | 136 M | 109 M | 94.8 M | 129 M | - | - |
Total Shareholders Equity |
143 M | 154 M | 212 M | 286 M | 287 M | 272 M | 288 M | 264 M | 263 M | 223 M | 211 M | 178 M | 136 M | 109 M | 94.8 M | 85.2 M | 82.1 M | 60.8 M |
All numbers in USD currency
Quarterly Balance Sheet Anika Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
23.8 M | 22.8 M | 23.2 M | 23.6 M | 24 M | 25.2 M | 25.8 M | 26.3 M | 26.9 M | - | 27.8 M | 28.3 M | 28.8 M | 29.2 M | - | 18.8 M | 19.2 M | 19.6 M | 20.1 M | 20.5 M | 356 K | 25 M | 50 M | 468 K | - | 21.4 M | - | 21.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.8 M | 7.2 M | 7.6 M | 8 M | 8 M | 8 M | 8 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M |
Deferred Revenue |
229 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52 K | 74 K | - | - | - | - | - | - | - | - | - | - | 33.9 K | 35.9 K | 140 K | 24.5 K | 12.9 K | 24.5 K | 24.5 K | 180 K | 180 K | 180 K | 180 K | 2.88 M | 2.88 M | 2.88 M | 2.88 M | 2.87 M | 2.87 M | 2.87 M | 2.87 M |
Retained Earnings |
55.7 M | 60.5 M | 62.8 M | 66.8 M | 71.7 M | 93.5 M | 123 M | 124 M | 128 M | - | 198 M | 200 M | 211 M | 216 M | - | 223 M | 226 M | 231 M | 231 M | 224 M | 221 M | 221 M | 221 M | 221 M | 245 M | 245 M | 245 M | 245 M | 218 M | 218 M | 218 M | 218 M | 200 M | 200 M | 200 M | 200 M | 168 M | 168 M | 168 M | 168 M | 136 M | 136 M | 136 M | 136 M | 105 M | 105 M | 105 M | 105 M | 66.6 M | 66.6 M | 66.6 M | 66.6 M | 46 M | 46 M | 46 M | 46 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M |
Total Assets |
179 M | 189 M | 188 M | 191 M | 203 M | 231 M | 263 M | 264 M | 271 M | - | 329 M | 339 M | 349 M | 348 M | - | 342 M | 348 M | 353 M | 363 M | 362 M | 366 M | 366 M | 366 M | 366 M | 331 M | 331 M | 331 M | 331 M | 279 M | 279 M | 279 M | 279 M | 283 M | 283 M | 283 M | 283 M | 240 M | 240 M | 240 M | 240 M | 236 M | 236 M | 236 M | 236 M | 193 M | 194 M | 194 M | 194 M | 156 M | 156 M | 156 M | 156 M | 142 M | 142 M | 142 M | 142 M | 133 M | 133 M | 133 M | 133 M |
Cash and Cash Equivalents |
41 M | 58 M | 53.2 M | 53.4 M | 55.6 M | 62.4 M | 62.8 M | 68.6 M | 72.9 M | - | 65.1 M | 79.7 M | 86.3 M | 87.8 M | - | 90.3 M | 94.4 M | 91 M | 97.2 M | 94.6 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 157 M | 157 M | 157 M | 157 M | 89 M | 89 M | 89 M | 89 M | 133 M | 133 M | 133 M | 133 M | 104 M | 104 M | 104 M | 104 M | 111 M | 111 M | 111 M | 111 M | 100 M | 100 M | 100 M | 100 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M |
Book Value |
179 M | 189 M | 188 M | 191 M | 203 M | 231 M | 263 M | 264 M | 271 M | - | 329 M | 339 M | 349 M | 348 M | - | 342 M | 348 M | 353 M | 363 M | 362 M | 366 M | 366 M | 366 M | 366 M | 331 M | 331 M | 331 M | 331 M | 279 M | 279 M | 279 M | 279 M | 283 M | 283 M | 283 M | 283 M | 240 M | 240 M | 240 M | 240 M | 236 M | 236 M | 236 M | 236 M | 193 M | 194 M | 194 M | 194 M | 156 M | 156 M | 156 M | 156 M | 142 M | 142 M | 142 M | 142 M | 133 M | 133 M | 133 M | 133 M |
Total Shareholders Equity |
134 M | 147 M | 148 M | 148 M | 154 M | 180 M | 210 M | 209 M | 212 M | 270 M | 274 M | 278 M | 286 M | 285 M | 286 M | 286 M | 287 M | 290 M | 287 M | 277 M | 272 M | 272 M | 272 M | 272 M | 288 M | 288 M | 288 M | 288 M | 264 M | 264 M | 264 M | 264 M | 263 M | 263 M | 263 M | 263 M | 223 M | 223 M | 223 M | 223 M | 211 M | 211 M | 211 M | 211 M | 178 M | 178 M | 178 M | 178 M | 136 M | 136 M | 136 M | 136 M | 109 M | 109 M | 109 M | 109 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Anika Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
